Cargando…
RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper speci...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115561/ https://www.ncbi.nlm.nih.gov/pubmed/35600358 http://dx.doi.org/10.3389/fonc.2022.891812 |
_version_ | 1784709945583730688 |
---|---|
author | Sartorius, Kurt Antwi, Samuel O. Chuturgoon, Anil Roberts, Lewis R. Kramvis, Anna |
author_facet | Sartorius, Kurt Antwi, Samuel O. Chuturgoon, Anil Roberts, Lewis R. Kramvis, Anna |
author_sort | Sartorius, Kurt |
collection | PubMed |
description | Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions. |
format | Online Article Text |
id | pubmed-9115561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91155612022-05-19 RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? Sartorius, Kurt Antwi, Samuel O. Chuturgoon, Anil Roberts, Lewis R. Kramvis, Anna Front Oncol Oncology Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9115561/ /pubmed/35600358 http://dx.doi.org/10.3389/fonc.2022.891812 Text en Copyright © 2022 Sartorius, Antwi, Chuturgoon, Roberts and Kramvis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Sartorius, Kurt Antwi, Samuel O. Chuturgoon, Anil Roberts, Lewis R. Kramvis, Anna RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? |
title | RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? |
title_full | RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? |
title_fullStr | RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? |
title_full_unstemmed | RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? |
title_short | RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? |
title_sort | rna therapeutic options to manage aberrant signaling pathways in hepatocellular carcinoma: dream or reality? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115561/ https://www.ncbi.nlm.nih.gov/pubmed/35600358 http://dx.doi.org/10.3389/fonc.2022.891812 |
work_keys_str_mv | AT sartoriuskurt rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality AT antwisamuelo rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality AT chuturgoonanil rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality AT robertslewisr rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality AT kramvisanna rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality |